Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis



Rating:

Share or cite this content

Citations should be made in the following way:
C. Agostini (Padova, Italy). The future of targeted therapies for sarcoidosis. Annual Congress 2005 - Biological agents in the therapy of sarcoidosis

Member's Comments

No comment yet.

Related content which might interest you: Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis Source: Eur Respir J 2009; 34: 1376-1382 Year: 2009 How do antigen presenting cells see pathogens and cells? Source: Annual Congress 2006 - Targeting innate immunity in respiratory diseases Year: 2006 Tuberculosis therapy: past, present and future Source: Eur Respir J 2002; 20: 87S-94S Year: 2002 Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 IL-17 and Th17-cells as markers of disease progression in pediatric allergic diseases. A therapeutic approach in an "in vitro" models Source: Annual Congress 2011 - T-cell subsets Year: 2011 Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017 Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 Can intermediate monocytes predict response to infliximab therapy in sarcoidosis? Source: Eur Respir J 2016; 48: 1242-1245 Year: 2016 T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease Source: Eur Respir J 2007; 30: 383-390 Year: 2007 The adaptive immune system, autoimmunity and COPD: lessons from human studies Source: Annual Congress 2007 - T- and B-cells in COPD: a role for adaptive immunity in the pathogenesis of COPD? Year: 2007 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Delivery of siRNA to the lungs and airways Source: Annual Congress 2005 - Selective gene knockout - the use of small interference RNA Year: 2005 ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010 Dynamic of proinflammatory cytokines system and nonspecific markers of inflammation in patients with COPD before and after treatment with broncholitics Source: Eur Respir J 2006; 28: Suppl. 50, 38s Year: 2006 Immunotherapy improves inflammatory cytokines, humoral immunity and cellular immunity in septic patients Source: Annual Congress 2010 - Pulmonary infections and sepsis Year: 2010 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 COPD: inflammatory mechanisms and systemic consequences Source: Eur Respir Mon 2013; 59: 13-27 Year: 2013 Chemokines, innate and adaptive immunity, and respiratory disease Source: Eur Respir J 2002; 19: 350-355 Year: 2002 Role of altered immune response in CF and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012